Roadmap

2012
2012-11-15

Company

Following the acquisition by Power of the Dream Ventures, Genetic Immunity embarks on implementing a product oriented development strategy.
2013
2013-05-15

Regulatory process

We hire our regulatory agent, DJA Global Pharma, to handle all FDA correspondence.
2013-08-15

FDA

We submit a request with the United States Food and Drug Administration for DermaVir to be considered a Breakthrough Therapy
2014
2014-03-20

FDA Request

Following our FDA submission the agency responds with a request for additional infomation, the Clinical Study Reports of our three completed clinical trials.
2014-09-01

Clinical Study Reports

Work commences to complete our study report. This work is delayed by funding shortage.
2017
2017-05-01

ICO Planning

After a thorough review of all available options we decide to raise funds needed to complete our FDA documentation via an Initial Coin Offering, rather than the usual venture capital route. ICO planning begins.
2018
2018-03-01

HIV License granted to Russia

We are proud to announce that effective March 1st, 2018 we have granted an exclusive HIV technology license to our new Russian pharma partner. As part of the agreement we will develop a Clade A vaccine (predominant clade in Russia), with our new partner receiving exclusive rights to market it in..Read More
2018-03-30

1st presale

30% discount to ICO price. Tokens are available at $0.70. Total supply = 1,000,000
2018-04-15

2nd Presale

20% discount to ICO price. Tokens are available at $0.80. Total supply = 2,000,000
2018-04-30

3rd Presale

10% discount to ICO price. Tokens are available at $0.90. Total supply = 3,000,000
2018-05-15

Initial Coin Offering

Tokens are available at $1.00. Total supply = 4,000,000
2018-05-30

ICO completed

2018-06-01

Digital Personal Medicine Team

Assemble MyGeneticImmunity Digital Personal Medicine team to start development of our companion diagnostic site where user will be able to register, host their DNA and HLA information and find the optimal vaccine treatment available for a specific disease. MyGeneticImmunity will launch at the end of 2019 following FDA approval.
2018-06-01

Clinical Study Reports

Preparation of Clinical Study Reports for our Phase I, Phase I/II and Phase II trials.
2018-09-01

My Genetic Immunity site development

Once MyGeneticImmunity team is assembled development work continues on refining existing product prototype incorporating blockchain technology. Estimated completion time, with FDA approval.
2019
2019-01-10

Clinical Study Reports completed

Phase I, Phase I/II and Phase II study reports completed and filed with the United States Food and Drug Administration. Once filed we will request a Type C meeting to discuss Breakthrough Therapy, fast-track designation and fastest path to marketing approval.
2019-03-14

Expected FDA Type C meeting

2019-04-10

My Genetic Immunity beta launched

Beta testing of MyGeneticImmunity software platform begins – built on blockchain.

Read our Whitepaper